760 related articles for article (PubMed ID: 15065696)
1. Calcium channel blockers in the prevention of end stage renal disease: a review.
Derwa A; Peeters P; Vanholder R
Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
[TBL] [Abstract][Full Text] [Related]
2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
3. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
4. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
5. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
Boner G; Cao Z; Cooper ME
Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
[TBL] [Abstract][Full Text] [Related]
6. Renal protection and antihypertensive drugs: current status.
Salvetti A; Mattei P; Sudano I
Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
[TBL] [Abstract][Full Text] [Related]
7. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
8. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.
Taylor AA; Sunthornyothin S
Curr Hypertens Rep; 1999 Oct; 1(5):446-53. PubMed ID: 10981104
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
Nosadini R; Tonolo G
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
[TBL] [Abstract][Full Text] [Related]
10. Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature.
Steuber TD; Lee J; Holloway A; Andrus MR
Ann Pharmacother; 2019 Oct; 53(10):1050-1059. PubMed ID: 30966785
[No Abstract] [Full Text] [Related]
11. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
12. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
13. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hypertension in chronic renal insufficiency.
Locatelli F; Manzoni C; Marcelli D
J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
Ritz E; Orth SR; Strzelczyk P
J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
[TBL] [Abstract][Full Text] [Related]
17. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
19. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
[TBL] [Abstract][Full Text] [Related]
20. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
Weir MR
J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
